Medication use and polypharmacy in patients referred to a tertiary gastroenterology practice

1. TINETTI ME, BOGARDUS ST, AGOSTINI JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004; 351(27):2870–2874.10.1056/NEJMsb04245815625341Search in Google Scholar

2. GANDHI TK, WEINGART SN, BORUS J, SEGER AC, PETERSON J, BURDICK E, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003; 348(16):1556–1564.10.1056/NEJMsa02070312700376Search in Google Scholar

3. KANTOR ED, REHM CD, HAAS JS, CHAN AT, GIOVANUCCI EL. Trends in prescription drug use among adults in the United States from 1999–2012. Jama. 2015; 314(17):1818–1831.10.1001/jama.2015.13766475216926529160Search in Google Scholar

4. EVERHART JE, RUHL CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009; 136(2):376–386.10.1053/j.gastro.2008.12.01519124023Search in Google Scholar

5. IMHANN F, BONDER MJ, VILA AV, FU J, MUJAGIC Z, VORK L, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016; 65(5):740–748.10.1136/gutjnl-2015-310376485356926657899Search in Google Scholar

6. SPIEGEL BM, CHEY WD, CHANG L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Am J Gastroenterol. 2008; 103(12):2972–2976.10.1111/j.1572-0241.2008.01992.x294908419086951Search in Google Scholar

7. HOLZER P. Treatment of opioid-induced gut dysfunction. Expert Opin Investig Drugs. 2007; 16(2):181–194.10.1517/13543784.16.2.18117243938Search in Google Scholar

8. LACY BE. Effects of Opioids on Esophageal Dysfunction. Gastroenterol Hepatol (N Y). 2016; 12(5):323–325.Search in Google Scholar

9. CAMILLERI M, LEMBO A, KATZKA DA. Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits. Clin Gastroenterol Hepatol. 2017; 15(9):1338–1349.10.1016/j.cgh.2017.05.014556567828529168Search in Google Scholar

10. CHIAL HJ, CAMILLERI M, BURTON D, THOMFORDE G, OLDEN KW, STEPHENS D. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol. 2003; 284(1):G130–137.10.1152/ajpgi.00266.200212488239Search in Google Scholar

11. HALPERT A, DALTON CB, DIAMANT NE, TONER BB, HU Y, MORRIS CB, et al. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol. 2005; 100(3):664–671.10.1111/j.1572-0241.2005.30375.x15743366Search in Google Scholar

12. ZHONG W, MARADIT-KREMERS H, ST AUVER JL, YAWN BP, EBBERT JO, ROGER VL, et al. Age and sex patterns of drug prescribing in a defined American population. Mayo Clin Proc. 2013; 88(7):697–707.10.1016/j.mayocp.2013.04.021375482623790544Search in Google Scholar

13. FRANSSEN FM, SPRUIT MA, WOUTERS EF. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011; 6:493–501.10.2147/COPD.S24443320676522069360Search in Google Scholar

14. HOFFMAN F, VAN DES BUSSCHE H, WIESE B, SCHON G, KOLLER D, EISELE M, et al. Impact of geriatric comorbidity and polypharmacy on cholinesterase inhibitors prescribing in dementia. BMC Psychiatry. 2011; 11:190.10.1186/1471-244X-11-190326215422145796Search in Google Scholar

15. PATEL PJ, HAYWARD KL, RUDRA R, HORSFALL LU, HOSSAIN F, WILLIAMS S, et al. Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management. Medicine (Baltimore). 2017; 96(26):e6761.10.1097/MD.0000000000006761550001628658094Search in Google Scholar

16. CALDERON-LARRANAGA A, GIMENO-FELIU LA, GONZALES-RUBIO F, POBLADOR-PLOU B, LAILA-SAN JOSE M, ABAD-DIEZ JM, et al. Polypharmacy patterns: unravelling systematic associations between prescribed medications. PLoS One. 2013; 8(12):e84967.10.1371/journal.pone.0084967386992024376858Search in Google Scholar

17. MASNOON A, SHAKIB S, KALISCH-ELLETT L, CAUGHEY GE. What is polypharmacy? A systematic review of definitions. BMC Geriatrics 2017; 17:230.10.1186/s12877-017-0621-2563556929017448Search in Google Scholar

18. BEUSCART JB, PETIT S, GAUTIER S, WIERRE P, BALCAEN T, LEFEBVRE JM, et al. Polypharmacy in older patients: identifying the need for support by a community pharmacist. BMC Geriatrics 2019; 19(1):277.10.1186/s12877-019-1276-y680248131638909Search in Google Scholar